Navigation Links
DATATRAK Announces the Award of New Studies from European Pharmaceutical Clients
Date:10/16/2009

CLEVELAND, Oct. 16 /PRNewswire-FirstCall/ -- DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded two new studies from European Sponsor clients. These new studies will seek to enroll a broad range of patients across both Europe as well as the Indian subcontinent.

"We are delighted to have won this new business and consider it to be a direct result of our continued hard work in providing world-class professional services around our innovative eClinical platform," said Laurence Birch, DATATRAK's Chairman of the Board. "More and more Sponsors and CROs are recognizing, and taking advantage of, the benefits of being able to conduct their drug programs on a single, unified and multi-faceted eClinical solution, rather than getting entangled in a maze of integrated clinical solutions with several third parties and solution providers. While other vendors continue to acquire disparate solutions in an effort to broaden their own offerings, we continue to see evidence that our strategy of having developed a single database eClinical solution is gaining more and more recognition."

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through a unified multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK Exhibiting at the DIAs 3rd Annual Clinical Forum in Nice, France
2. DATATRAK Launches New Web Site
3. Advance Research Associates Joins DATATRAKs CRO Connect Program(TM)
4. DATATRAK Announces New Products and Features at DIA San Diego
5. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
6. DATATRAK International, Inc. Announces First Quarter Results for 2009
7. German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAKs CRO Connect Program(TM)
8. Keypoint Joins DATATRAKs CRO Connect Program(TM)
9. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
10. DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results for 2008
11. DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy ... May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... surgeon reveals that infants born with severe congenital diaphragmatic hernia have better survival ... born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... engineer of patented products, announces the Gyrociser, an exercise invention which aids in ... $2 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with ... in an upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and ... butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product research and development ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... , April 27, 2016 ... of the  "Global Anesthesia Disposables Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ,The global anesthesia disposables ... CAGR of 4.03% during the period 2016-2020.  ... major threat to patients, safety. Organizations like ...
Breaking Medicine Technology: